MERCK Kommanditgesellschaft auf Aktien Stock Forecast, Price & News

-0.15 (-0.09 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume219,526 shs
Average VolumeN/A
Market Capitalization$22.57 billion
P/E Ratio33.33
Dividend Yield0.81%
30 days | 90 days | 365 days | Advanced Chart
Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MERCK Kommanditgesellschaft auf Aktien and its competitors with MarketBeat's FREE daily newsletter.

MERCK Kommanditgesellschaft auf Aktien logo

About MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.15 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Frequently Asked Questions

What stocks does MarketBeat like better than MERCK Kommanditgesellschaft auf Aktien?

Wall Street analysts have given MERCK Kommanditgesellschaft auf Aktien a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MERCK Kommanditgesellschaft auf Aktien wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MERCK Kommanditgesellschaft auf Aktien's next earnings date?

MERCK Kommanditgesellschaft auf Aktien is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for MERCK Kommanditgesellschaft auf Aktien

How has MERCK Kommanditgesellschaft auf Aktien's stock been impacted by Coronavirus?

MERCK Kommanditgesellschaft auf Aktien's stock was trading at €98.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 76.9% and is now trading at €174.60.
View which stocks have been most impacted by COVID-19

Is MERCK Kommanditgesellschaft auf Aktien a good dividend stock?

MERCK Kommanditgesellschaft auf Aktien pays an annual dividend of €1.40 per share and currently has a dividend yield of 0.81%. The dividend payout ratio of MERCK Kommanditgesellschaft auf Aktien is 26.72%. This payout ratio is at a healthy, sustainable level, below 75%.
View MERCK Kommanditgesellschaft auf Aktien's dividend history.

Who are MERCK Kommanditgesellschaft auf Aktien's key executives?

MERCK Kommanditgesellschaft auf Aktien's management team includes the following people:
  • Ms. Belen Garijo Lopez M.D., Chair of Exec. Board & CEO (Age 61, Pay $5M)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 53, Pay $4.07M)
  • Dr. Kai Beckmann, CEO of Electronics & Member of the Exec. Board (Age 56, Pay $4.15M)
  • Mr. Peter Guenter, CEO of Healthcare Bus. & Member of Exec. Board (Age 59)
  • Dr. Matthias J. Heinzel, CEO of Life Science Sector & Member of Exec. Board (Age 55)
  • Mr. Gerhard Schmitz, Head of Global Accounting (Age 58)
  • Mr. Dirk Toepfer, Chief Information Officer
  • Mr. Constantin Fest, Head of Investor Relations (Age 44)
  • Dr. Friederike Rotsch, Group Gen. Counsel and Head of Group Legal & Compliance (Age 49)
  • Ms. Barbara Weiland, Chief Compliance Officer (Age 47)

Who are some of MERCK Kommanditgesellschaft auf Aktien's key competitors?

What other stocks do shareholders of MERCK Kommanditgesellschaft auf Aktien own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MERCK Kommanditgesellschaft auf Aktien investors own include AbbVie (ABBV), Chevron (CVX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Eli Lilly and (LLY), Medtronic (MDT), AT&T (T), Adobe (ADBE), Aldeyra Therapeutics (ALDX) and Amgen (AMGN).

What is MERCK Kommanditgesellschaft auf Aktien's stock symbol?

MERCK Kommanditgesellschaft auf Aktien trades on the ETR under the ticker symbol "MRK."

What is MERCK Kommanditgesellschaft auf Aktien's stock price today?

One share of MRK stock can currently be purchased for approximately €174.60.

How much money does MERCK Kommanditgesellschaft auf Aktien make?

MERCK Kommanditgesellschaft auf Aktien has a market capitalization of $22.57 billion and generates $17.80 billion in revenue each year.

How many employees does MERCK Kommanditgesellschaft auf Aktien have?

MERCK Kommanditgesellschaft auf Aktien employs 57,850 workers across the globe.

What is MERCK Kommanditgesellschaft auf Aktien's official website?

The official website for MERCK Kommanditgesellschaft auf Aktien is

How can I contact MERCK Kommanditgesellschaft auf Aktien?

The company can be reached via phone at 49 6151 72 0.

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.